VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Learnings from clinical trial failure in Parkinson’s disease

Joaquim Ferreira, MD, PhD, University of Lisbon, Lisbon, Portugal, discusses the learnings from negative clinical trials in Parkinson’s disease. Clinical trials can fail for many reasons that are not always known, but in the neurodegenerative disease space, the lack of effective disease-modifying therapies is one of them. Past trials have highlighted the importance of conducting adequate Phase I and II trials with appropriate biomarkers that can help the design of later phase trials but also generate informative studies. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.

Disclosures

Received grants from GlaxoSmithKline, Grunenthal, Fundação MSD (Portugal), TEVA, MSD, Allergan, Novartis, Medtronic and Angelini. Received consultancy and speaker fees and participated in advisory boards for GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion Pharmaceuticals, Zambon, Affiris, Roche, ONO and SK Chemicals.